Patient empowerment is a hot topic in many areas of medicine. Particularly so for diseases that are more complex to manage, and present with symptoms that aren’t immediately obvious and which vary greatly among individuals.

Multiple sclerosis (MS) is one such disease. An estimated 2,500,000 people in the world have MS, a condition which can cause a broad range of symptoms and affect multiple parts of the body.

Given that each person with the condition is affected in a different way, patient empowerment is a key aspect of delivering a high quality of care to patients, a fact which was clear from research presented at the recent European Committee for Treatment and Research in Multiple Sclerosis congress - ECTRIMS for short.

In Episode 6 of The Pharma Letter Podcast, we are joined by Nidia Afonso, EMEA compound market access lead at Janssen, and part of a team which presented significant new data on patient empowerment at the event.